Phosphoinositide 3-kinase catalytic subunit alpha isoform, Mechanistic target of rapamycin (PI3Kα, mTOR)

The targets Phosphoinositide 3-kinase catalytic subunit alpha isoform (PI3Kα) and Mechanistic target of rapamycin (mTOR) refer to two separate but mechanistically linked enzymes within the PI3K/AKT/mTOR intracellular signaling pathway, each widely acknowledged as key therapeutic targets in cancer and other diseases. The Phosphoinositide 3-kinase catalytic subunit alpha isoform (PI3Kα; encoded by PIK3CA) is a lipid kinase that phosphorylates phosphoinositides, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) upon activation by growth factors or other stimuli. This initiates signaling cascades that regulate cell survival, proliferation, growth, and metabolism. Activating mutations in PIK3CA are common drivers in several cancer types[6][9]. The Mechanistic target of rapamycin (mTOR) is a large serine/threonine kinase and central node in the PI3K/AKT/mTOR pathway, integrating energy status, nutrient availability, growth factor, and stress signals to control cell growth, protein synthesis, metabolism, and autophagy[1][3][4][9]. mTOR functions as the catalytic core of two separate complexes, mTORC1 and mTORC2, which differ in regulatory proteins and downstream signaling. mTOR is dysregulated in many human cancers and is targeted by approved drugs such as rapalogs and investigational inhibitors. Combined targeting of PI3Kα and mTOR is an active strategy in cancer therapy due to pathway feedback and redundancy[3][6][9].

Other names

p110αPIK3CAphosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alphaFRAP1FK506-binding protein 12-rapamycin-associated protein 1mammalian target of rapamycinmechanistic target of rapamycin kinase

PI3Kα inhibitors: inhibit lipid kinase activity, preventing PIP3 generation and downstream AKT activation; mTOR inhibitors: inhibit kinase activity of mTOR complex (mostly mTORC1), suppressing protein synthesis and cell growth.